

# ForPatients

by Roche

CNS Tumors Brain Tumor Solid Tumors Cancer

## Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions

### Trial Status

Active, not recruiting

### Trial Runs In

7 Countries

### Trial Identifier

NCT02650401 CO40778

RXDX-101-03

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.

### Hoffmann-La Roche

Sponsor

### Phase 1

Phase

NCT02650401 CO40778 RXDX-101-03

Trial Identifiers

### *Eligibility Criteria:*

#### Gender

All

#### Age

>=0 Years & <= 18 Years

#### Healthy Volunteers

No